首页> 外文期刊>Bone marrow transplantation >Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1.
【24h】

Risk associations between HLA-DPB1 T-cell epitope matching and outcome of unrelated hematopoietic cell transplantation are independent of HLA-DPA1.

机译:HLA-DPB1 T细胞表位匹配与不相关造血细胞移植结局之间的风险关联独立于HLA-DPA1。

获取原文
获取原文并翻译 | 示例
       

摘要

HLA-DP antigens are beta-alpha heterodimers encoded by polymorphic HLA-DPB1 and -DPA1 alleles, respectively, in strong linkage disequilibrium (LD) with each other. Non-permissive unrelated donor (UD)-recipient HLA-DPB1 mismatches across three different T-cell epitope (TCE) groups are associated with increased mortality after hematopoietic SCT (HCT), but the role of HLA-DPA1 is unclear. We studied 1281 onco-hematologic patients after 10/10 HLA-matched UD-HCT facilitated by the National Marrow Donor Program. Non-permissive mismatches defined solely by HLA-DPB1 TCE groups were associated with significantly higher risks of TRM compared to permissive mismatches (hazard ratio (HR) 1.30, confidence interval (CI) 1.06-1.53; P=0.009) or allele matches. Moreover, non-permissive HLA-DPB1 TCE group mismatches in the graft versus host (GvH) direction significantly decreased the risk of relapse compared to permissive mismatches (HR 0.55, CI 0.37-0.80; P=0.002) or allele matches. Splitting each group into HLA-DPA1*02:01 positive or negative, in frequent LD with HLA-DPB1 alleles from two of the three TCE groups, or into HLA-DPA1 matched or mismatched, did not significantly alter the observed risk associations. Our findings suggest that the effects of clinically non-permissive HLA-DPB1 TCE group mismatches are independent of HLA-DPA1, and that selection of donors with non-permissive DPB1 TCE mismatches in GvH direction might provide some protection from disease recurrence.
机译:HLA-DP抗原是分别由多态性HLA-DPB1和-DPA1等位基因编码的β-alpha异二聚体,彼此之间具有很强的连锁不平衡(LD)。跨三个不同的T细胞表位(TCE)组的非许可无关供体(UD)受体HLA-DPB1错配与造血SCT(HCT)后死亡率增加相关,但HLA-DPA1的作用尚不清楚。我们通过国家骨髓捐献者计划促进了10/​​10 HLA匹配的UD-HCT后对1281例血液肿瘤患者进行了研究。与允许的错配(危险比(HR)1.30,置信区间(CI)1.06-1.53​​; P = 0.009)或等位基因匹配相比,仅由HLA-DPB1 TCE组定义的非允许错配与TRM风险显着更高。此外,与允许的错配(HR 0.55,CI 0.37-0.80; P = 0.002)或等位基因匹配相比,在移植物与宿主(GvH)方向上的非允许的HLA-DPB1 TCE组错配显着降低了复发的风险。将来自三个TCE组中的两个的HLA-DPB1等位基因的频繁LD中的每组分为HLA-DPA1 * 02:01阳性或阴性,或匹配或不匹配的HLA-DPA1,均不会显着改变观察到的风险关联。我们的发现表明,临床上不允许的HLA-DPB1 TCE组错配的影响独立于HLA-DPA1,并且选择GvH方向上不允许DPB1 TCE错配的供体可能为疾病复发提供一定的保护。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号